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It is estimated that 360 million people were affected by diabetes mellitus (DM) in 
2011 with the great majority (namely 95%) being affected by type 2 DM (T2DM). Most 
importantly, approximately half of these individuals are not aware of this diagnosis. 
In addition, another 300 million individuals are at future risk of developing T2DM, 
including people with increased fasting glucose (IFG), impaired glucose tolerance 
(IGT), gestational DM, and euglycaemic insulin resistance (IR).
This is a summary of the European Society of Cardiology’s (ESC) Guidelines on 
the management of diabetes mellitus (DM), pre-diabetes, and cardiovascular disease 
(CVD) developed in collaboration with the European Association for the Study of 
Diabetes (EASD). These guidelines were released in October 2013 with the aim to 
assist clinicians towards an evidence-based management decisions.
The classification of DM is based on recommendations from the World Health 
Organization (WHO), and the American Diabetes Association. The definition, classifi-
cation, and diagnosis of abnormalities of glucose metabolism are provided in Figure 1.
Cardiovascular disease (CVD) is the main cause of death in diabetic individuals, 
since more than half of deaths in subjects with DM are attributed to CVD. These 
data highlight the necessity of diagnosing and accordingly treating CVD in diabetic 
patients. In the relevant guidelines the following algorithm outlines the principles for 
the diagnosis and management of CVD in DM patients with a primary diagnosis of 
DM or a primary diagnosis of CVD (Figure 2). The guidelines however specify that 
the recommended investigations should be considered according to individual needs 
and clinical judgment and they are meant as a general recommendation.
The treatment targets when we deal with patients with DM or IGT and CVD are 
summarized in figure 3.
The main points included in the relevant guidelines concerning the approach and 
decision making in patients with diabetes are summarized in the following subsections:
1 .  P r e v e n t i o n  o f  d i a b e t e s  i n  P a t i e n t s  
w i t h  i m P a i r e d  g l u c o s e  t o l e r a n c e  ( i g t )
- Lifestyle counseling, based on modest weight loss and increased physical activity, 
prevents or delays progression to DM in individuals with IGT, and should be offered 
to such persons.
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ABI = ankle brachial index
ACE-I = angiotensin converting enzyme 
inhibitor
ACS = acute coronary syndrome
ADA = American Diabetes Association
AF = atrial fibrillation
ARB = angiotensin receptor blocker
CAD = coronary artery disease
CVD = cardiovascular disease
DM = diabetes mellitus
EASD = European Association for the 
Study of Diabetes
ECG = electrocardiogram
ESC = European Society of Cardiology
FPG = fasting plasma glucose
IFG = impaired fasting glucose
IGT = impaired glucose tolerance
IR = insulin resistance
LVEF = left ventricular ejection fraction
MI = myocardial infarction
MRA = mineralocorticoid receptor 
antagonist
NYHA = New York heart Association
PAD = peripheral artery disease
T2DM = type 2 diabetes mellitus
WHO = World Health Organization
Conflict of Interest: none declared
120
HOSPITAL CHRONICLES 2014, VOLUME 9, SUPPLEMENT 1: «ATHENS CARDIOLOGY UPDATE 2014»
figure 1.
figure 2.
NEWER COMBINED (ESC & EASD) 2013 GUIDELINES FOR DM & CVD
121
figure 3.
2 .  i d e n t i f Y i n g  P a t i e n t s  w i t h 
d i a b e t e s  a n d  t h o s e  a t  r i s k  
f o r  d e v e l o P i n g  d m
 - Primary screening for potential T2DM in the general 
population is recommended to start with a non-invasive 
DM risk score (e.g. the Finnish Diabetes Risk Score or 
FINDRISC; www.diabetes.fi/english) to identify individu-
als at high risk of T2DM in whom hemoglobin (Hb) A1c 
and fasting plasma glucose (FPG) should be determined.
 - In CVD patients no diabetes risk score is needed, but an 
oral glucose tolerance test (OGTT) is indicated if HbA1c 
and/or FPG are normal, since people who belong to these 
groups may often have DM disclosed only by an elevated 
two-hour post load glucose (2hPG).
3 .  m i c r o v a s c u l a r  c o m P l i c a t i o n s
 - Screening for the presence of retinopathy should be con-
sidered on an annual basis in patients with T2DM.
 - An HbA1c <7% and a blood pressure <140/85 mmHg 
are recommended for primary prevention of retinopathy 
related to DM.
 - Multifactorial therapy is recommended when retinopathy 
is progressing rapidly.
4 .  c a r d i o v a s c u l a r  r i s k 
a s s e s s m e n t  i n  P a t i e n t s  w i t h 
d Y s g l Y c a e m i a
 - Patients with DM and at least one other cardiovascular risk 
factor or target organ damage should be considered as at 
very high risk and all other patients with DM as being at 
high risk.
 - Estimate the urinary albumin excretion rate when perform-
ing risk stratification in patients with DM.
5 .  r e c o m m e n d a t i o n s  o n  l i f e  s t Y l e 
m o d i f i c a t i o n s  i n  d i a b e t e s
 - Smoking cessation guided by structured advice is recom-
mended in all subjects with DM.
 - Total fat intake should be <35%, saturated fat <10%, and 
monounsaturated fatty acids >10% of total energy.
 - Dietary fibre intake should be >40 g/day (or 20 g/1000 
Kcal/day) in the prevention of T2DM and control of DM.
 - Any diet with reduced energy intake can be recommended 
to lower excessive body weight in DM.
 - Vitamin or micronutrient supplementation to reduce the 
risk of CVD in DM is not recommended.
 - Moderate to vigorous physical activity of ≥150 min/week 
is recommended for the prevention and control of T2DM, 
and prevention of CVD in DM.
 - Aerobic exercise and resistance training are recommended 
in the prevention and control of T2DM, but best when 
combined.
6 .  r e c o m m e n d a t i o n s  
f o r  P a t i e n t s  w i t h  d m  a n d  c v d
 - For patients with DM and stable coronary artery disease 
(CAD), and angiotensin converting enzyme inhibitor 
(ACE-I) or angiotensin receptor blocker (ARB) are indi-
cated to reduce the risk for cardiovascular events.
 - Statin therapy is recommended in patients with DM and 
CAD to reduce the risk for cardiovascular events.
 - ACE-I (or an ARB if ACE-I not tolerated), and a beta-
blocker are recommended in patients with systolic heart 
failure and T2DM to reduce mortality and hospitalizations.
 - A mineralocorticoid receptor antagonist (MRA) is recom-
mended for all patients with persisting symptoms (NYHA 
class II–IV) and a left ventricular ejection fraction (LVEF) 
≤35% despite treatment with an ACE-I (or an ARB if an 
ACE-I is not tolerated) and a beta-blocker, to reduce the 
risk of heart failure hospitalization and premature death.
 - Thiazolidinediones should not be used in patients with 
122
HOSPITAL CHRONICLES 2014, VOLUME 9, SUPPLEMENT 1: «ATHENS CARDIOLOGY UPDATE 2014»
heart failure and T2DM since water retention may worsen 
or provoke heart failure.
 - Oral anticoagulation with vitamin K antagonists or a new 
oral anticoagulant is recommended in DM patients with 
atrial fibrillation (AF) if not contraindicated.
 - Screening for AF should be considered since it is common 
in patients with DM and increases morbidity and mortality.
 - It is recommended that patients with DM have annual 
screening to detect peripheral artery disease (PAD) and 
measurement of the ankle brachial index (ABI) to detect 
lower extremity artery disease.
 - It is recommended that patients with PAD and DM have 
LDL-cholesterol (LDL-C) lowered to <1.8 mmol/L (<70 
mg/dL), that they stop smoking, and have their blood pres-
sure controlled to <140/85 mmHg.
Finally, multidisciplinary teams and nurse-led programs 
should be considered to support lifestyle change and self-
management.
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